Ann: Bard1 and Sienna Cancer Diagnostics announce merger, page-61

This is clearly in favour of BD1 long term, while the share price might not currently reflect it. With the acquisition of SDX IP, physical lab and accessibility to the market via different channels which would not have been possible without a CR this is an absolute steal. This latest merger and lack of market updates strongly suggests that there are bigger moves at play. SDX was due for a correction at some point, it was extremely undervalued and this announcement has been that catalyst. Great opportunity for the big hands at 4 to 5.4c to average down a bit and a good entry point for those that have had Bard1 on their radar. Congratulations to both BD1 and SDX holders, let the good news flow!